<DOC>
	<DOCNO>NCT02815592</DOCNO>
	<brief_summary>The purpose study administer BMS-986012 Combination Platinum Etoposide First-line Therapy Extensive Small Cell Lung Cancer .</brief_summary>
	<brief_title>Trial BMS-986012 Combination With Platinum Etoposide</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Male Females 18 year age old Pulmonary SCLC document histology cytology Extensive disease ( Stage IV ) SCLC Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Prior systemic therapy lung cancer Symptomatic brain metastasis Grade 2 peripheral neuropathy Active chronic infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV Other active malignancy prior malignancy within 2 year Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>